164 related articles for article (PubMed ID: 23860958)
1. Compatibility of intravenous fosaprepitant with intravenous 5-HT3 antagonists and corticosteroids.
Sun S; Schaller J; Placek J; Duersch B
Cancer Chemother Pharmacol; 2013 Sep; 72(3):509-13. PubMed ID: 23860958
[TBL] [Abstract][Full Text] [Related]
2. Compatibility and Stability of VARUBI (Rolapitant) Injectable Emulsion Admixed with Intravenous Palonosetron Hydrochloride Injection and Dexamethasone Sodium Phosphate Injection.
Wu G; Powers D; Yeung S; Chen F
Int J Pharm Compd; 2018; 22(1):76-85. PubMed ID: 29385388
[TBL] [Abstract][Full Text] [Related]
3. Compatibility and Stability of VARUBI (Rolapitant) Injectable Emulsion Admixed with Intravenous Granisetron Hydrochloride.
Wu G; Powers D; Yeung S; Chen F; Neelon K
Int J Pharm Compd; 2018; 22(1):86-94. PubMed ID: 29385389
[TBL] [Abstract][Full Text] [Related]
4. Assessing physico-chemical compatibility of concomitantly diluted antiemetics including palonosetron-HCl and fosaprepitant dimeglumine.
Lipp HP; Gfrörer W
Cancer Chemother Pharmacol; 2014 Feb; 73(2):435-6. PubMed ID: 24220934
[No Abstract] [Full Text] [Related]
5. Reply to: Assessing physico-chemical compatibility of concomitantly diluted antiemetics including palonosetron-HCl and fosaprepitant dimeglumine.
Duersch B
Cancer Chemother Pharmacol; 2014 Feb; 73(2):437. PubMed ID: 24395440
[No Abstract] [Full Text] [Related]
6. Fosaprepitant dimeglumine (MK-0517 or L-785,298), an intravenous neurokinin-1 antagonist for the prevention of chemotherapy induced nausea and vomiting.
Van Belle SJ; Cocquyt V
Expert Opin Pharmacother; 2008 Dec; 9(18):3261-70. PubMed ID: 19040346
[TBL] [Abstract][Full Text] [Related]
7. Impact of 5-HT(3) RA selection within triple antiemetic regimens on uncontrolled highly emetogenic chemotherapy-induced nausea/vomiting.
Schwartzberg L; Jackson J; Jain G; Balu S; Buchner D
Expert Rev Pharmacoecon Outcomes Res; 2011 Aug; 11(4):481-8. PubMed ID: 21711119
[TBL] [Abstract][Full Text] [Related]
8. Neurokinin 1 receptor antagonists in the prevention of chemotherapy-induced nausea and vomiting: focus on fosaprepitant.
Rapoport BL; Jordan K; Weinstein C
Future Oncol; 2018 Jan; 14(1):77-92. PubMed ID: 29130344
[TBL] [Abstract][Full Text] [Related]
9. Compatibility and Stability of Rolapitant Injectable Emulsion Admixed with Dexamethasone Sodium Phosphate.
Wu G; Yeung S; Chen F
Int J Pharm Compd; 2017; 21(1):66-75. PubMed ID: 28346199
[TBL] [Abstract][Full Text] [Related]
10. Doxofylline and methylprednisolone sodium succinate are stable and compatible under normal injection conditions.
Xu F; Feng E; Su L; Xu G
Pak J Pharm Sci; 2013 Mar; 26(2):261-5. PubMed ID: 23455194
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of triplet regimen antiemetic therapy for chemotherapy-induced nausea and vomiting (CINV) in bone and soft tissue sarcoma patients receiving highly emetogenic chemotherapy, and an efficacy comparison of single-shot palonosetron and consecutive-day granisetron for CINV in a randomized, single-blinded crossover study.
Kimura H; Yamamoto N; Shirai T; Nishida H; Hayashi K; Tanzawa Y; Takeuchi A; Igarashi K; Inatani H; Shimozaki S; Kato T; Aoki Y; Higuchi T; Tsuchiya H
Cancer Med; 2015 Mar; 4(3):333-41. PubMed ID: 25533447
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of fosaprepitant + 5HT3 receptor antagonist + dexamethasone in patients with germ cell tumors undergoing 5-day cisplatin-based chemotherapy: a Hoosier Cancer Research Network study.
Adra N; Albany C; Brames MJ; Case-Eads S; Johnson CS; Liu Z; Fausel CA; Breen T; Hanna NH; Hauke RJ; Picus J; Einhorn LH
Support Care Cancer; 2016 Jul; 24(7):2837-42. PubMed ID: 26838019
[TBL] [Abstract][Full Text] [Related]
13. Antiemetic Prophylaxis with Fosaprepitant and 5-HT
Cabanillas Stanchi KM; Willier S; Vek J; Schlegel P; Queudeville M; Rieflin N; Klaus V; Gansel M; Rupprecht JV; Flaadt T; Binder V; Feuchtinger T; Lang P; Handgretinger R; Döring M
Drug Des Devel Ther; 2020; 14():3915-3927. PubMed ID: 33061297
[TBL] [Abstract][Full Text] [Related]
14. Compatible stability of methylprednisolone sodium succinate and tropisetron in 0.9% sodium chloride injection.
Peng C; Lei JX
Eur J Hosp Pharm; 2020 Mar; 27(e1):e58-e62. PubMed ID: 32296507
[TBL] [Abstract][Full Text] [Related]
15. A phase 3, randomized, double-blind study of single-dose fosaprepitant for prevention of cisplatin-induced nausea and vomiting: results of an Indian population subanalysis.
Maru A; Gangadharan VP; Desai CJ; Mohapatra RK; Carides AD
Indian J Cancer; 2013; 50(4):285-91. PubMed ID: 24369195
[TBL] [Abstract][Full Text] [Related]
16. Compatibility of ondansetron hydrochloride and methylprednisolone sodium succinate in multilayer polyolefin containers.
Bougouin C; Thelcide C; Crespin-Maillard F; Maillard C; Kinowski JM; Favier M
Am J Health Syst Pharm; 2005 Oct; 62(19):2001-5. PubMed ID: 16174836
[TBL] [Abstract][Full Text] [Related]
17. Physical and chemical stability of palonosetron HCl in 4 infusion solutions.
Trissel LA; Xu QA
Ann Pharmacother; 2004 Oct; 38(10):1608-11. PubMed ID: 15328393
[TBL] [Abstract][Full Text] [Related]
18. Aprepitant: drug-drug interactions in perspective.
Aapro MS; Walko CM
Ann Oncol; 2010 Dec; 21(12):2316-2323. PubMed ID: 20488873
[TBL] [Abstract][Full Text] [Related]
19. Fosaprepitant: a neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting.
Navari RM
Expert Rev Anticancer Ther; 2008 Nov; 8(11):1733-42. PubMed ID: 18983233
[TBL] [Abstract][Full Text] [Related]
20. Aprepitant plus palonosetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy.
Gao HF; Liang Y; Zhou NN; Zhang DS; Wu HY
Intern Med J; 2013 Jan; 43(1):73-6. PubMed ID: 22141732
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
